Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment‐Related Adverse Events From the CheckMate 040 Study

BACKGROUND: CheckMate 040 assessed the efficacy and safety of nivolumab in patients with advanced hepatocellular carcinoma (HCC). Understanding the safety profile of nivolumab is needed to support the management of treatment‐related adverse events (TRAEs). This analysis assessed the safety of nivolu...

Descripción completa

Detalles Bibliográficos
Autores principales: Julien, Karen, Leung, Hiu Tung, Fuertes, Carmen, Mori, Megumi, Wang, Miao‐Jen, Teo, Jocelyn, Weiss, Lisa, Hamilton, Sara, DiFebo, Holly, Noh, Yoon Jin, Galway, Aralee, Koh, Jane, Brutcher, Edith, Zhao, Huanyu, Shen, Yun, Tschaika, Marina, To, Yue‐Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Hepatobiliary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543234/
https://www.ncbi.nlm.nih.gov/pubmed/33400305
http://dx.doi.org/10.1634/theoncologist.2019-0591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543234/
https://www.ncbi.nlm.nih.gov/pubmed/33400305
http://dx.doi.org/10.1634/theoncologist.2019-0591

Ejemplares similares